<DOC>
	<DOCNO>NCT02688868</DOCNO>
	<brief_summary>The purpose study evalute clinical safety effectiveness release specification ( 2.25mm ) FirehawkTM Sirolimus target-eluting coronary stent system .</brief_summary>
	<brief_title>Evaluation New Specifications ( 2.25mm ) FirehawkTM Treatment Coronary Heart Disease ( Firehawk_2.25 )</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<criteria>1 . 1880 year age , male nonpregnant woman ; 2 . Evidence silent ischemia , stability patient old myocardial infarction unstable angina ; 3 . Primary target lesion , situ coronary artery disease ; 4 . Target lesion length ≤ 60mm , target lesion diameter 2.75mm 4.0mm ( Visual method ) ; 5 . The target lesion diameter stenosis ≥ 70 % ( Visual method ) ; 6 . Each target lesion implantation stent ( Firehawk stand ) ; 7 . With indication coronary artery bypass surgery ; 8 . To understand purpose testing , voluntary inform consent , patient undergo invasive imaging followup . 1 . Within 1 month acute myocardial infarction ; 2 . Chronic total occlusion ( TIMI grade 0 flow surgery ) , leave main coronary artery disease , mouth lesion , multiplevessel lesion , branch diameter ≥ 2.5mm bifurcation lesion vascular lesion bridge ; 3 . Severe calcify lesion successfully expand distort lesion suitable stent delivery ; 4 . Instent Restenosis lesion ; 5 . Intracoronary implantation brand stent within 1 year ; 6 . Severe congestive heart failure ( NYHA class III ) , leave ventricular ejection fraction &lt; 40 % ( ultrasound leave ventricular angiography ) ; 7 . Preoperative renal function serum creatinine &gt; 2.0mg/DL ; 8 . Bleeding , active gastrointestinal ulcer , brain hemorrhage subarachnoid hemorrhage half year history ischemic stroke , antiplatelet agent would allow anticoagulant therapy contraindication patient undergo antithrombotic therapy ; 9 . Aspirin , clopidogrel , heparin , contrast agent , poly lactic acid polymer rapamycin allergy ; 10 . The patient 's life expectancy le 12 month ; 11 . Top participate drug medical device meet primary study endpoint clinical trial time frame ; 12 . Researchers determine patient compliance poor , unable complete study accordance requirement ; 13 . Heart transplantation patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>